Report initial results from the first VIR-7831 Phase 3 study
Delivered by the deadline
AI-assessed · human review in progress Found and assessed by AI from the cited sources. Shown with its evidence; it is not counted in any Kept Score until confirmed.
- Announced
- 19 Feb 2021
- Due
- 31 Mar 2021
- Delivered
- March 2021
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“with initial results from the first of the Phase 3 studies expected in the first quarter of 2021”
What we found
Evidence strength A What the grades mean
The company's 10-Q reports that in March 2021 it announced the VIR-7831 arm of the NIH ACTIV Phase 3 trial met initial pre-specified criteria, within the Q1 2021 deadline.
-
A Vir Biotechnology, Inc. 10-K filed 2022-02-28
“In March 2021, we announced that the sotrovimab arm of the NIH's ACTIV-3 clinical trial met initial pre-specified criteria, and no safety signals were reported.” ✓ confirmed on the page
-
A Vir Biotechnology, Inc. 10-Q filed 2021-05-06
“In March, we announced that the VIR-7831 arm of the National Institutes of Health's, or NIH's, ACTIV (Accelerating COVID-19 Therapeutic Interventions and Vaccines) Program Phase 3 clinical trial met initial pre-specified criteria, and no safety signals were reported.” ✓ confirmed on the page
Checked 26 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical readout late
- Indicative materiality
- High rules
- Action
- Report
- Deliverable
- Initial results from first VIR-7831 Phase 3 study
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- Medium
- Specificity
- High
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Claude (Anthropic), read the company's later filings and recorded the outcome with a quoted passage.
Not yet confirmed. Shown on the record, but it will not count in any score until it is confirmed. How verification works
Are you Vir Biotechnology, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2021-VIR-024133 · Corrections policy